ESC 365 - COMMANDER HF - Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Back

ESC Premium Access

COMMANDER HF - Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Session: Hot Line Session 3

Topic: Pharmacotherapy

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Event: ESC Congress 2018

Congress Presentation

About the speaker

Professor Faiez Zannad

University of Lorraine, Vandoeuvre-Les-Nancy (France)

100 presentations

4 followers

19 more presentations in this session

Opening question - ATTR-ACT Trial.

Access

Slides

Video

ATTR-ACT Trial - Efficacy and Safety of Tafamidis in Transthyretin Amyloid Cardiomyopathy

Speaker: Professor C. Rapezzi (Ferrara, IT)

Discussant review - ATTR-ACT.

Speaker: Professor J. George (Rehovot, IL)

Access

Slides

Video

Questions from the audience and discussion.

Access

Concluding question - ATTR-ACT Trial.

Access

Slides

Video

Access the full session

Hot Line Session 3

Speakers: Professor F. Zannad, Professor C. Rapezzi, Professor J. George

Access

About the event

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress

COMMANDER HF - Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure

About the speaker

Professor Faiez Zannad

19 more presentations in this session

Opening question - ATTR-ACT Trial.

ATTR-ACT Trial - Efficacy and Safety of Tafamidis in Transthyretin Amyloid Cardiomyopathy

Discussant review - ATTR-ACT.

Questions from the audience and discussion.

Concluding question - ATTR-ACT Trial.

Access the full session

Hot Line Session 3

About the event

ESC Congress 2018

ESC 365 is supported by